Moclobemide

Chemical name

п-Хлор-N-(2-морфолиноэт��л)бензамид

Gross

C13-H17-Cl-N2-O2

Characteristics

Black and white with кремоватым white crystalline powder. Easily soluble in water and alcohol.

Of drugs

Drugs, the antidepressant, psihostimulirutee. Selectively and reversible MAO ingibiruet type A inhibits serotonin metabolism (mostly), norarenalina, dopamine, causing their accumulation in the synaptic junctions. Optimal antidepressant effect dispensed with the oppression MAO at 60-80%. Improves mood and психомоторную activity. Decreases symptoms of depression-disforiu, block, the inability to concentrate, eliminates symptoms sociofobi improve Sna.posle intake of rapidly and completely absorbed. C_mah achieved through 1hr Bioavailability of 40-80%. Equilibrium concentration in plasma is after one week of admission. The blood is associated with 80% of the protein (mostly albuminami). Easily passes tissue barriers apparent volume of about 1.2 l / mm Almost completely biotransformiroetsa (oxidized). Report the news mostly in the form of metabolites (unchanged to less than 1%). The Cl - 20-50 l / h. T_1/2 - 1-4 pm The main effects are in the first week of therapy.

Indications

Depression different etiology : when маниакально-депресси��ном psychosis, various forms of schizophrenia, chronic alcoholism, and senile inwaluie, rocket and nervous, sociofobia.

Contraindications

Hypersensitivity, the acute consciousness admission selegilina, pregnancy, breast-feeding (at the end of treatment), children's age.

Side-Effects

Dizziness, headache, sleep disturbance, ажитация, anxiety, irritability, спутанность consciousness парестезии, lack of, dry mouth, nausea, heartburn, feeling of fullness stomach, diarrhea, constipation, skin reaction (rash, itching, urticaria, tides).

Patient interaction

Enhance and prolong the effect симпатомиметиков and opiates. Increase the likelihood of adverse events of the central nervous system in combination with petidine, claumipraminom, dekstrometorfanom. Zimetidin biotransformatia slows.

Precautions

Be wary when appoint tireotoxicose and feohromotsytome (perhaps the gipertenziveh reactions). Is not recommended for patients whose initiation is the major clinical manifestation of disease. In shizofrenicescom shizoaffeguom or psychosis may increase schizophrenic symptoms (it is necessary in this case to move to neiroleptiki). Patients with elevated AD should refrain from the excessive consumption of foods containing tiramin. At the beginning of therapy to control speed reactions.

Dosing and Administration

Inside, the food-300-600 mg, 2-3 reception. Initial daily doses of 300 mg, with the heavy depression may be increased to 600 mg. The recommended dose for no earlier than one hour after the start of therapy. When a clinical effect of lower dose.

Directory → Neurotropic funds → 24.2.1 → Moclobemide